VERIGRAFT

Executive Summary

VERIGRAFT is a Swedish biotechnology company pioneering personalized, tissue-engineered grafts for vascular and nerve reconstruction. Founded in 2016 and headquartered in Gothenburg, the company leverages a proprietary platform to create patient-specific veins, arteries, nerves, and heart valves. By using the patient's own cells, VERIGRAFT aims to eliminate immune rejection without requiring lifelong immunosuppression, addressing a critical unmet need in transplantation medicine. Its technology holds potential to transform treatment for conditions such as peripheral artery disease, hemodialysis access, and nerve injuries, where current synthetic or allograft options suffer from poor patency and immune complications. The company is currently in Phase 2/3 clinical development, focusing on lead indications in vascular repair. With a strong underlying science and a growing body of clinical evidence, VERIGRAFT is positioned to become a leader in regenerative medicine. Successful completion of its pivotal trials could pave the way for first-in-class approvals, offering patients durable, biocompatible grafts. The company's progress is closely watched by investors and clinicians alike, given the high unmet demand for improved graft solutions. VERIGRAFT's innovative approach and clinical momentum underscore its potential to reshape standard of care in reconstructive surgery.

Upcoming Catalysts (preview)

• Q3 2026Phase 2/3 Interim Data Readout for Vascular Graft55% success
• Q4 2026FDA Breakthrough Therapy Designation40% success
• Q2 2026Strategic Partnership with Major Medical Device Company30% success